Journal of Regenerative Medicine

Rapid Communication A SCITECHNOL JOURNAL

Mesenchymal Stem Cells in Tissue Repair: Mechanisms and Therapeutic Applications

Yeon Lee*

Department of Internal Medicine, Seoul National University Hospital, Korea

***Corresponding author:** Yeon Lee, Department of Internal Medicine, Seoul National University Hospital, Korea, E-mail: lee.yeon@snu.ac.kr

Citation: Lee Y (2024) Mesenchymal Stem Cells in Tissue Repair: Mechanisms and Therapeutic Applications. J Regen Med 13:6.

Received: 01-Nov-2024, Manuscript No. JRGM-24-152613, **Editor assigned:** 02-Nov-2024, PreQC No. JRGM-24-152613 (PQ), **Reviewed:** 16-Nov-2024, QC No. JRGM-24-152613, **Revised:** 22-Nov-2024, Manuscript No. JRGM-24-152613 (R), **Published:** 27-Nov-2024, DOI:10.4172/2325-9620.1000336

Introduction

Mesenchymal stem cells (MSCs) have garnered significant attention over the past few decades due to their remarkable potential in tissue repair and regenerative medicine. These multipotent cells, initially identified in the bone marrow, have since been found in a variety of tissues, including adipose tissue, umbilical cord blood, and dental pulp. Their ability to differentiate into a range of cell types such as osteocytes, chondrocytes, and adipocytes, coupled with their anti-inflammatory and immunomodulatory properties, positions MSCs as a promising candidate for therapeutic applications in tissue repair and regeneration [1].

MSCs are characterized by their ability to adhere to plastic in culture, express specific surface markers (such as CD73, CD90, and CD105), and differentiate into mesodermal lineages. One of their defining features is the capacity for self-renewal, which allows them to proliferate while maintaining their undifferentiated state. This is crucial in tissue repair, where a large number of cells may be required for regeneration. Furthermore, MSCs secrete a wide array of bioactive molecules, including growth factors and cytokines, which play essential roles in modulating the local environment to promote tissue healing [2].

MSCs contribute to tissue repair through several key mechanisms. First, their differentiation potential enables them to replace damaged or dead cells by becoming specific cell types needed for tissue regeneration, such as bone or cartilage cells. Second, MSCs possess paracrine activity, meaning they release signaling molecules that influence neighboring cells. This paracrine effect is crucial for initiating and sustaining the repair process by promoting angiogenesis (the formation of new blood vessels), reducing inflammation, and inhibiting apoptosis (programmed cell death) [3].

A third critical mechanism is MSCs' immunomodulatory function. MSCs can suppress the immune response, preventing excessive inflammation that might otherwise damage healthy tissue during repair. They achieve this by interacting with various immune cells, including T-cells, B-cells, and macrophages. By downregulating inflammatory cytokines and promoting the production of anti-inflammatory factors, MSCs create a favorable environment for tissue regeneration. One of the most well-studied areas for MSC applications is in the treatment of musculoskeletal disorders, including osteoarthritis, cartilage damage, and bone fractures. In these contexts, MSCs can differentiate into chondrocytes to repair cartilage or osteoblasts to regenerate bone. Clinical studies have shown that intra-articular injection of MSCs into damaged joints can improve cartilage repair, reduce pain, and enhance joint function in patients with osteoarthritis. Similarly, MSCs have been explored as a therapeutic option for bone regeneration in cases of non-union fractures, with promising results [4].

MSCs have also shown promise in the treatment of cardiovascular diseases, particularly in myocardial infarction (heart attack) and heart failure. In these conditions, the damaged heart tissue loses its ability to function properly, leading to reduced cardiac output. MSCs injected into the infarcted area can differentiate into cardiomyocytes and vascular endothelial cells, thereby contributing to the repair of both the heart muscle and its supporting vasculature. Additionally, the paracrine factors released by MSCs can promote the survival of native cardiac cells and stimulate angiogenesis, further enhancing the regenerative process [5].

Preclinical and clinical studies have demonstrated that MSC therapy can improve heart function, reduce scar formation, and enhance overall patient outcomes following a heart attack. However, the long-term benefits and the most effective delivery methods for MSCs in cardiac repair are still under investigation. The ability of MSCs to cross the blood-brain barrier and their immunomodulatory properties make them attractive candidates for treating neurodegenerative disorders, such as Parkinson's disease, multiple sclerosis, and spinal cord injuries. In these contexts, MSCs can help by reducing inflammation in the nervous system, protecting neurons from apoptosis, and even promoting the differentiation of neural cells [6].

For instance, in spinal cord injuries, MSCs have been shown to enhance functional recovery by promoting axonal growth and remyelination of nerve fibers. Similarly, in neurodegenerative diseases like Parkinson's, MSCs can support the survival of dopaminergic neurons, the cell type that degenerates in this condition. However, challenges remain regarding the efficient delivery of MSCs to the central nervous system and the long-term survival of transplanted cells in the hostile environment of neurodegeneration. MSCs' immunomodulatory abilities have also opened avenues for their use in autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. In these diseases, the immune system mistakenly attacks the body's own tissues, causing chronic inflammation and tissue damage. MSCs, by modulating immune cell function, can reduce this aberrant immune activity, thereby alleviating the symptoms of these diseases and potentially halting disease progression [7].

Clinical trials have shown that MSC infusions can reduce inflammation and improve quality of life in patients with autoimmune conditions. However, the precise mechanisms by which MSCs achieve this and the durability of their effects are still subjects of ongoing research. Despite their potential, several challenges exist in the clinical translation of MSC therapies. One of the main concerns is the variability in MSCs depending on their tissue of origin. For example, MSCs derived from adipose tissue may have different properties compared to those from bone marrow. This heterogeneity can affect their efficacy in different therapeutic contexts. Moreover, the long-term safety of MSC-based therapies remains a concern, as there is a potential risk of unwanted differentiation, such as fibrosis or tumor formation [8].

Another challenge is the scalability of MSC production for widespread clinical use. While MSCs can be expanded in culture, prolonged culture periods can lead to cellular senescence, reducing their therapeutic potential. As a result, researchers are investigating ways to optimize MSC isolation, expansion, and storage to preserve their regenerative capacity. Advancements in gene editing and tissue engineering offer exciting possibilities for enhancing MSC therapy. For example, MSCs can be genetically modified to overexpress certain factors that enhance their regenerative or immunomodulatory properties. This could improve their therapeutic efficacy in specific disease contexts. Additionally, combining MSCs with biomaterials, such as hydrogels or scaffolds, could provide structural support for tissue repair and promote the survival and integration of transplanted cells [9].

Moreover, researchers are exploring the use of extracellular vesicles (EVs) derived from MSCs as an alternative therapeutic approach. These EVs contain proteins, lipids, and nucleic acids that mimic many of the beneficial effects of MSCs, such as promoting tissue repair and modulating the immune response. Since EVs do not face the same concerns as live cell therapies, such as immune rejection or unwanted differentiation, they represent a promising future direction in regenerative medicine [10].

Conclusion

Mesenchymal stem cells offer tremendous potential in tissue repair due to their ability to differentiate, secrete bioactive molecules, and modulate the immune system. From musculoskeletal disorders to cardiovascular and neurodegenerative diseases, MSC-based therapies are already showing promise in both preclinical and clinical settings. However, challenges remain in optimizing their therapeutic use, including issues of cell variability, scalability, and safety. Continued research into enhancing MSC function, developing standardized protocols, and exploring novel delivery systems will be crucial to realizing their full potential in regenerative medicine.

References

1. Selvasandran K, Makhoul G, Jaiswal PK, Jurakhan R, Li L, et al. (2018) A tumor necrosis factor-α and hypoxia-induced secretome therapy for myocardial repair. Ann Thorac Surg;105(3):715-23.
2. Oh EJ, Lee HW, Kalimuthu S, Kim TJ, Kim HM, et al. (2018) In vivo migration of mesenchymal stem cells to burn injury sites and their therapeutic effects in a living mouse model. J Control Release;279:79-88.
3. Kawai T, Katagiri W, Osugi M, Sugimura Y, Hibi H, et al. (2015) Secretomes from bone marrow–derived mesenchymal stromal cells enhance periodontal tissue regeneration. Cytotherapy;17(4):369-81.
4. Folestad E, Kunath A, Wågsäter D (2018) PDGF-C and PDGF-D signaling in vascular diseases and animal models. Mol Aspects Med;62:1-1.
5. Zhang SJ, Song XY, He M, Yu SB (2016) Effect of TGF-β1/SDF-1/CXCR4 signal on BM-MSCs homing in rat heart of ischemia/perfusion injury. Eur Rev Med Pharmacol Sci;20(5).
6. Gnecchi M, Danieli P, Malpasso G, Ciuffreda MC (2016) Paracrine mechanisms of mesenchymal stem cells in tissue repair. Mesenchymal Stem Cells: Methods and Protocols:123-46.
7. Lin W, Xu L, Zwingenberger S, Gibon E, Goodman SB, Li G (2017) Mesenchymal stem cells homing to improve bone healing. J Orthop Transl;9:19-27.
8. Deng QJ, Xu XF, Ren J (2018). Effects of SDF-1/CXCR4 on the repair of traumatic brain injury in rats by mediating bone marrow derived mesenchymal stem cells. Cell Mol Neurobiol;38:467-77.
9. Zou C, Song G, Luo Q, Yuan L, Yang L (2011) Mesenchymal stem cells require integrin β1 for directed migration induced by osteopontin in vitro. In Vitro Cell Dev Biol Anim;47:241-50.
10. Liu L, Luo Q, Sun J, Song G (2019) Cytoskeletal control of nuclear morphology and stiffness are required for OPN-induced bone-marrow-derived mesenchymal stem cell migration. Int J Biochem Cell Biol;97(4):463-70.